Replimune develops oncolytic immunotherapies, treatments built on engineered viruses that target skin cancers. It last closed at $19.69 on Nov 17, down 8.03% on the day. REPL reports earnings on Tue, Feb 2, 2027. The average 12-month price target from 4 analysts is $24.00 (+21.9% from the last close), with a high of $31.00 and a low of $17.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 4 dark pool prints totaling $5.2M, the largest $1.5M.
Each firm's latest rating on REPL in the past 90 days
Average 12-month target
$24.00
▲ 21.9% upside
Based on 4 analysts who set a price target on REPL in the past 90 days. The average target is $24.00, with a high of $31.00 and a low of $17.00, compared with the last close of $19.69.
Highest target$31.00
Average target$24.00
Lowest target$17.00
Latest rating changes
Piper SandlerMaintained
Nov 16Buy$27
Leerink PartnersTarget raised
Oct 29Buy$17 → $31
Roth MKMInitiated
Sep 25Buy$17
JP MorganTarget raised
Aug 26Buy$20 → $21
JP MorganMaintained
Aug 7Buy$20
Date
Firm
Action
Rating
Price target
Nov 16
Piper Sandler
Maintained
Buy
$27
Oct 29
Leerink Partners
Target raised
Buy
$17 → $31
Sep 25
Roth MKM
Initiated
Buy
$17
Aug 26
JP Morgan
Target raised
Buy
$20 → $21
Aug 7
JP Morgan
Maintained
Buy
$20
Loading…
Technical Analysis
REPL · as of the Nov 17 close · updated after every close
Uptrend
The stock is 7% above its 20 day and 24% above its 50 day average. It is 49% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 58). The nearest support is the Pivot S1 at $19.01, and the nearest resistance the Pivot at $20.28.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 6.8%/day
Key levels
$23.4152 week high+18.9%
$23.41Swing high (Nov 10)+18.9%
$20.96Pivot R1+6.4%
$20.28Pivot+3.0%
$19.69Last close
$19.01Pivot S1−3.5%
$18.3320 day average−6.9%
$14.9950 day average−23.9%
$14.90Swing low (Aug 31)−24.3%
$13.65100 day average−30.7%
$10.13200 day average−48.6%
$1.5052 week low−92.4%
Indicators
RSI (14)
58.00
Middle of its range
Neutral
MACD
2.17
Above its signal line
Bullish
Stochastic
72.2
Middle of its range
Neutral
ADX (14)
41.2
Strong uptrend
Williams %R
-51.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
39.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−4.7%
Change over 10 sessions
Bearish
ATR (14)
$1.33
Typical daily range, 6.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, nearing overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNear overbought
VolatilityNormal, 13.0%/day
Key levels
$23.4152 week high+18.9%
$23.41Swing high (Nov 10)+18.9%
$20.96Pivot R1+6.4%
$20.28Pivot+3.0%
$19.69Last close
$19.01Pivot S1−3.5%
$18.3320 day average−6.9%
$14.9950 day average−23.9%
$14.90Swing low (Aug 31)−24.3%
$13.65100 day average−30.7%
$10.13200 day average−48.6%
$1.5052 week low−92.4%
Indicators
RSI (14)
65.61
Strong, overbought above 70
Neutral
MACD
2.59
Above its signal line
Bullish
Stochastic
85.5
Near the top of its range
Overbought
ADX (14)
19.3
No clear trend
Williams %R
-29.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
163.0
Oversold below −100, overbought above 100
Overbought
Rate of change
+52.4%
Change over 10 sessions
Bullish
ATR (14)
$2.57
Typical daily range, 13.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for REPL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how REPL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow REPL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How REPL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REPL is in one of them and how their past REPL trades turned out.
Replimune is a biotechnology company based in Woburn, Massachusetts, that develops oncolytic immunotherapies for cancer. These treatments use an engineered herpes simplex virus to kill tumor cells directly and to stimulate the immune system against the cancer. Its lead candidate, RP1, is being studied mainly in advanced melanoma and other skin cancers, with patients as the intended users. The company's products are still in clinical development and are not yet sold.